Predictive value of SUV-based parameters derived from pre-treatment 18F-FLT PET/CT for short-term outcome with head and neck cancers
详细信息 查看全文
- 作者：Hiroshi Hoshikawa (1)
Yuka Yamamoto (2)
Terushige Mori (1)
Takehito Kishino (1)
Takashi Fukumura (1)
Yasushi Samukawa (1)
Nozomu Mori (1)
Yoshihiro Nishiyama (2) - 关键词：FLT ; PET/CT ; Metabolic tumor volume ; Total lesion proliferation ; SUVpeak ; Prognosis
- 刊名：Annals of Nuclear Medicine
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：28
- 期：10
- 页码：1020-1026
- 全文大小：270 KB
- 参考文献：1. Wong RJ, Lin DT, Sch?der H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of [18F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199-08. CrossRef
2. Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115:645-0. CrossRef
3. Minn H, Lapela M, Klemi PJ, Grénman R, Leskinen S, Lindholm P, et al. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907-1.
4. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, el El-Ghazi A, Lehmann W, et al. Standardized uptake value of 2-[18F] gluoro-2-deoxy-d -glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398-04. CrossRef
5. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86:512-. CrossRef
6. Schinagl DA, Span PN, Oyen WJ, Kaanders JH. Can FDG PET predict radiation treatment outcome in head and neck cancer? results of a prospective study. Eur J Nucl Med Mol Imaging. 2011;38:1449-8. CrossRef
7. Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck. 2009;31:195-01. CrossRef
8. Thorwarth D, Eschmann S, Holzner F, Paulsen F, Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol. 2006;80:151-. CrossRef
9. Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. comparison to histopathologic and clinical response evaluation. Radiother Oncol. 2008;89:278-6. CrossRef
10. Gulec SA, Suthar RR, Barot TC, Pennington K. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging. 2011;38:1289-5. CrossRef
11. Chu KP, Murphy JD, La TH, Krakow TE, Iagaru A, Graves EE, et al. Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. Int J Radiat Oncol Biol Phys. 2012;83:1521-. CrossRef
12. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:27-8. CrossRef
13. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut. 2003;52:1602-. CrossRef
14. Van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med. 2005;46:400-.
15. Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610-. Yamamoto (2)
Terushige Mori (1)
Takehito Kishino (1)
Takashi Fukumura (1)
Yasushi Samukawa (1)
Nozomu Mori (1)
Yoshihiro Nishiyama (2)
1. Department of Otolaryngology, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan
2. Department of Radiology, Faculty of Medicine, Kagawa University, Kagawa, Japan - ISSN：1864-6433
文摘
Objective The aim of this study was to investigate the predictive potential of pre-treatment 3-deoxy-3-[18F]-fluorothymidine (FLT) uptake parameters for short-term outcome of primary head and neck squamous cell cancer (HNSCC) patients. Patients and methods A total of 32 patients undergoing pre-treatment FLT positron emission tomography/computed tomography (PET/CT) from May 2010 to May 2013 were evaluated. Semi-quantitative assessment was used to determine mean, peak and maximum standardized uptake values (SUVmean, SUVpeak and SUVmax), metabolic tumor volume (MTV) and total lesion proliferation (TLP). Clinicopathologic factors and PET/CT parameters were analyzed for their association with 2-year loco-regional control (LRC) and overall survival (OS). Results The mean (±?SD) SUVmean, SUVpeak, SUVmax, MTV and TLP were 5.97?±?3.16, 6.71?±?3.75, 10.05?±?5.37, 7.31?±?8.05 and 44.95?±?52.82, respectively. In univariate analyses, N category was associated with OS (P?=?0.037). Increased MTV ?3?ml was associated with decreased LRC and OS (P?P?=?0.009 and 0.015, respectively). Regarding SUVs, only the SUVpeak was associated with LRC and OS (P?=?0.035 and 0.049, respectively). Conclusions Pre-treatment MTV is the most useful parameter with FLT PET/CT. TLP and SUVpeak may also provide important prognostic information for patients with HNSCCs.